PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31249661-7 2019 Real-time PCR analysis showed significant increases in PPARgamma and fatty acid binding protein 4 mRNA levels in rosiglitazone-treated cells, which were inhibited by TGF-beta1 treatment. Rosiglitazone 113-126 fatty acid binding protein 4 Homo sapiens 69-97 33990655-6 2021 We finally tested our hypothesis on human Mesenchymal Stromal Cells differentiated to osteocytes and adipocytes confirming the beneficial effect of docosahexaenoic acid (DHA) omega-3 FA during treatment with rosiglitazone, through the down-regulation of adipogenic genes, such as adipsin and FABP4 along the PPARgamma/FABP4 axis, and reducing the capability of osteocytes to switch toward adipogenesis. Rosiglitazone 208-221 fatty acid binding protein 4 Homo sapiens 292-297 33990655-6 2021 We finally tested our hypothesis on human Mesenchymal Stromal Cells differentiated to osteocytes and adipocytes confirming the beneficial effect of docosahexaenoic acid (DHA) omega-3 FA during treatment with rosiglitazone, through the down-regulation of adipogenic genes, such as adipsin and FABP4 along the PPARgamma/FABP4 axis, and reducing the capability of osteocytes to switch toward adipogenesis. Rosiglitazone 208-221 fatty acid binding protein 4 Homo sapiens 318-323 29990545-9 2018 Rosiglitazone significantly upregulated expression of ADFP, PPARgamma, ELOVL4, and FABP4 by 9.6, 2.7, 2.6, and 3.3 fold on average (all P < 0.05 except for FABP4, P = 0.057) in hMGEC. Rosiglitazone 0-13 fatty acid binding protein 4 Homo sapiens 83-88 29990545-9 2018 Rosiglitazone significantly upregulated expression of ADFP, PPARgamma, ELOVL4, and FABP4 by 9.6, 2.7, 2.6, and 3.3 fold on average (all P < 0.05 except for FABP4, P = 0.057) in hMGEC. Rosiglitazone 0-13 fatty acid binding protein 4 Homo sapiens 156-161 26945682-11 2016 However, the ability of the PPARgamma ligand rosiglitazone to induce activation of a PPARgamma-driven luciferase reporter and induce expression of FABP4 was suppressed in AR-positive PC-3 cells. Rosiglitazone 45-58 fatty acid binding protein 4 Homo sapiens 147-152 22046439-0 2011 Serum A-FABP is increased and closely associated with elevated NT-proBNP levels in type 2 diabetic patients treated with rosiglitazone. Rosiglitazone 121-134 fatty acid binding protein 4 Homo sapiens 6-12 22046439-2 2011 In this study we investigated the possible role of A-FABP in the development of cardiac dysfunction related to rosiglitazone treatment. Rosiglitazone 111-124 fatty acid binding protein 4 Homo sapiens 51-57 22046439-5 2011 After the 48-week rosiglitazone treatment period, serum levels of both A-FABP and NT-proBNP increased progressively and significantly (P<0.01). Rosiglitazone 18-31 fatty acid binding protein 4 Homo sapiens 71-77 22046439-9 2011 CONCLUSIONS/SIGNIFICANCE: Rosiglitazone-mediated increase of A-FABP is closely associated with the elevation of NT-proBNP, a well-established marker of cardiac dysfunction. Rosiglitazone 26-39 fatty acid binding protein 4 Homo sapiens 61-67 15273253-4 2004 Among the selected PPAR agonists, rosiglitazone and pioglitazone displayed the highest maximal efficacy (E(max)) on reporter-gene assays in COS-7 cells cotransfected by either a galactosidase 4-response element-based or a human aP2 promoter-based Luc reporter vector, along with either chimeric or full-length human PPAR expression plasmids. Rosiglitazone 34-47 fatty acid binding protein 4 Homo sapiens 228-231 21720879-4 2011 We assessed the level of FABP4 mRNA after treatment with testosterone, insulin, and rosiglitazone in GCs from normal controls. Rosiglitazone 84-97 fatty acid binding protein 4 Homo sapiens 25-30 21720879-7 2011 FABP4 mRNA expression was up-regulated by testosterone, insulin, and rosiglitazone at different dosages. Rosiglitazone 69-82 fatty acid binding protein 4 Homo sapiens 0-5